Update on Diabetes in the Elderly and the Application of Current Therapeutics

Journal of the American Medical Directors Association

Volumn 8, Issue 8, 2007, Pages 489-492

  Mazza, Angela D ^a   Morley, John E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; AGE DISTRIBUTION; AGING; ANOREXIA; CLINICAL TRIAL; COGNITION; DIABETES MELLITUS; DIABETIC PATIENT; DIET THERAPY; DRUG HALF LIFE; EDITORIAL; ELDERLY CARE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LONG TERM CARE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYPHARMACY; PREVALENCE; SIDE EFFECT; VASCULAR DISEASE; WEIGHT CONTROL; WEIGHT REDUCTION;

EID: 34948896984     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2007.07.007     Document Type: Editorial

References (66)

1. Morley J.E. Diabetes mellitus: A major disease of older persons. J Gerontol A Biol Sci Med Sci 55 (2000) M255-M256
2. Zarowitz B.J., Tangalos E.G., Hollenack K., and O'Shea T. The application of evidence-based principles of care in older persons (issue 3): Management of diabetes mellitus. J Am Med Dir Assoc 7 (2006) 234-240
3. McNabney M.K., Pandya N., Iwuagwu C., et al. Differences in diabetes management of nursing home patients based on functional and cognitive status. J Am Med Dir Assoc 6 (2005) 375-382
4. Meyers R., Broton J.C., Woo-Rippe K.W., et al. Variability in glycosylated hemoglobin values in diabetic patients living in long-term care facilities. J Am Med Dir Assoc 8 (2007) 511-514
5. Haas L. Optimizing insulin use in Type 2 diabetes: role of basal and prandial insulin in long-term care facilities. J Am Med Dir Assoc 8 (2007) 502-510
6. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 29 (2006) 59 42
7. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 2002. Diabetes Care 26 (2003) 917-932
8. Johnson C.L., Rifkind B.M., Sempos C.T., et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 269 (1993) 3002-3008
9. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21 (1998) 518-524
10. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
11. Saydah S. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes mellitus. JAMA 291 (2004) 335-342
12. Stratmeyer E.S., Cauley J.A., Schwartz A.V., et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults. Arch Intern Med 165 (2005) 1612-1617
13. Volpato S., Leveille, Blaum C., et al. Risk factors of falls in older disabled women with diabetes: The Women's Health and Aging Study. J Gerontol 60A (2005) 1539-1545
14. Rodríguez-Saldańa J., Morley J.E., Reynoso M.T., et al. Diabetes mellitus in a subgroup of older Mexicans: prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality. J Am Geriatr Soc 50 (2002) 111-116
15. Miller D.K., Lui L.Y., Perry H.M., et al. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol A Biol Sci Med Sci 54 (1999) M230-M236
16. Roberts S.B., Hajkuk C.L., Howarth N.C., et al. Dietary variety predicts low body mass index and inadequate macronutrient and micronutrient intakes in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 60 (2005) 613-621
17. Rosenthal M.J., Fajardo M., Gilmore S., et al. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care 21 (1998) 231-235
18. Levenson S.A., and Morley J.E. Evidence rocks in long-term care, but does it roll?. J Am Med Dir Assoc 8 (2007) 493-501
19. American Diabetes Association. Evidence-based nutrition principles and recommendation for the treatment and prevention of diabetes and related complication. Diabetes Care 25 (2002) 202-212
20. American Diabetes Association. Nutrition recommendations and interventions for diabetes-2006. Diabetes Care 29 (2006) 2140-2157
21. Morley J.E., Kim M.J., Haren M.T., et al. Frailty and the aging male. Aging Male 8 (2005) 135-140
22. MacIntosh C., Morley J.E., and Chapman I.M. The anorexia of aging. Nutrition 16 (2000) 983-995
23. Morley J.E. Weight loss in the nursing home. J Am Med Dir Assoc 8 (2007) 201-204
24. Tariq S.H., Karcic E., Thomas D.R., et al. The use of no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Diet Assoc 101 (2001) 1463-1466
25. Coulston A.M., Mandelbaum D., and Reaven G.M. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 51 (1990) 67-71
26. Wedick N.M., Barrett-Connor E., Knoke J.D., and Wingard D.L. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: The Rancho Bernardo Study. J Am Geriatr Soc 50 (2002) 1810-1815
27. American Diabetes Association. Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association. Diabetes Care 30 Suppl 1 (2007) S48-S65
28. Sigal R.J., Kenny G.P., Wasserman D.H., and Castaneda-Sceppa C. Physical activity/exercise and type 2 diabetes. Diabetes Care 27 (2004) 2518-2537
29. Schwartz R.S. Exercise training in treatment of diabetes mellitus in elderly patient. Diabetes Care 13 Suppl 2 (1990) 77-85
30. Castaneda C., Layne J.E., Munoz-Orians L., et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 25 (2002) 2335-2341
31. Dunstan D.W., Daly R.M., Owen N., et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 25 (2002) 1729-1736
32. Mazza A.D., and Morley J.E. Metabolic syndrome in the older male population. Aging Male 10 (2007) 3-8
33. Banks W.A., Willoughby L.M., Thomas D.R., and Morley J.E. Insulin resistance syndrome in the elderly: Assessment of functional, biochemical, metabolic, and inflammatory status. Diabetes Care 29 (2007) [Epub ahead of print].
34. Berg A.H., Combs T.P., Du X., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
35. Combs T.P., Wagner J.A., Berger J., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
36. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368 (2006) 1096-1105
37. Marfella R., D'Amico M., Di Filippo C., et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: Effects of rosiglitazone treatment. J Am Coll Cardiol 47 (2006) 2444-2455
38. Cicero D.G., D'Angelo A., Gaddi A., et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 28 (2006) 679-688
39. Nissen N.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
40. Home P.D., Pocock S.T., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med (2007) 28-38
41. Nauck M.A., Niedereichholz U., Ettler R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273 (1997) 981-988
42. Hvidberg A., Nielsen M.T., Hilsted J., et al. Effect of glucagon-like peptide 1 (proglucagon 78-107 amide) on hepatic glucose production in healthy men. Metabolism 43 (1994) 104-108
43. Tang-Christensen M., Larsen P.J., Goke R., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271 (1996) 848-856
44. Flint A., Raben A., Astrup A., and Jolst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
45. Meneilly G.S., Veldhuis J.D., and Elahi D. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes. J Clin Endocrinol Metab 90 (2004) 6251-6256
46. Egan J.M., Clocquet A.R., and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 1282-1290
47. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117 (2004) 77-88
48. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
49. Buse J.B., Henry R.R., Han J., et al. Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
50. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
51. Kim D., MacDonell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30 (2006) 1487-1493
52. Ahren B., Simonsson E., Larsson H., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
53. Vella A., Bock G., Giesler P.D., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56 (2007) 1475-1480
54. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 141-151
55. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Ther 78 (2005) 675-688
56. Nauck M.A., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9 (2007) 194-205
57. Lee A., Patrick P., Wishart J., Horowitz M., and Morley J.E. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4 (2002) 329-335
58. DeLeon M.J., Chandurkar V., Albert S.G., and Mooradian A.D. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 56 (2002) 101-106
59. Gentilcore D., Bryant B., Wishart J.M., et al. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med 118 (2005) 1289
60. Morley J.E. Postprandial hypotension-the ultimate Big Mac Attack [editorial]. J Gerontol A Biol Sci Med Sci 56 (2001) M741-M743
61. Kim M.J., Rolland Y., Cepeda O., et al. Diabetes mellitus in older men. Aging Male 9 (2006) 139-147
62. Lee A., and Morley J.E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6 (1998) 47-53
63. Morley J.E., and Flood J.F. Effect of competitive antagonism of NO synthetase on weight and food intake in obese and diabetic mice. Am J Physiol 266 1 Pt 2 (1994) R164-R168
64. Kumar V.B., Bernardo A.E., Vyas K., et al. Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice. Life Sci 69 (2001) 2789-2799
65. Alam T., Weintraub N., and Weinreb J. What is the proper use of hemoglobin A1C monitoring in the elderly?. J Am Med Dir Assoc 7 3 Suppl (2006) S60-S64
66. Morley J.E. The elderly Type 2 diabetic patient: Special considerations. Diabet Med 15 Suppl 4 (1998) S41-S46